
Personalis PSNL
€ 6.95
-2.62%
Quartalsbericht 2025-Q3
hinzugefügt 04.11.2025
Personalis Betriebsaufwand 2011-2025 | PSNL
Betriebsaufwand Jährlich Personalis
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | 44.5 M | 25.6 M | 19.8 M | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 44.5 M | 19.8 M | 30 M |
Betriebsaufwand anderer Aktien in der Diagnostik & Forschung
| Name | Betriebsaufwand | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Akumin
AKU
|
778 M | - | -17.87 % | $ 25.9 M | ||
|
Centogene N.V.
CNTG
|
58 M | - | -6.23 % | $ 30.6 M | ||
|
Brainsway Ltd.
BWAY
|
29.2 M | $ 19.33 | 0.21 % | $ 99.4 M | ||
|
Burning Rock Biotech Limited
BNR
|
726 M | $ 20.97 | -1.38 % | $ 226 M | ||
|
Accelerate Diagnostics
AXDX
|
77.2 M | - | -61.36 % | $ 2.46 M | ||
|
Co-Diagnostics
CODX
|
45.3 M | $ 0.23 | -4.4 % | $ 6.75 M | ||
|
Biocept
BIOC
|
21.6 M | - | -13.05 % | $ 7.29 M | ||
|
Chembio Diagnostics
CEMI
|
28.5 M | - | 0.22 % | $ 16.8 M | ||
|
Castle Biosciences
CSTL
|
59.5 M | $ 39.53 | -1.4 % | $ 1.1 B | ||
|
BioNano Genomics
BNGO
|
41.3 M | $ 1.52 | - | $ 1.93 M | ||
|
DarioHealth Corp.
DRIO
|
62.2 M | $ 10.17 | 1.29 % | $ 289 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
59.4 M | - | - | $ 562 M | ||
|
DexCom
DXCM
|
1.69 B | $ 67.51 | 0.13 % | $ 26.1 B | ||
|
Danaher Corporation
DHR
|
6.71 B | $ 230.0 | -0.45 % | $ 168 B | ||
|
Exact Sciences Corporation
EXAS
|
2.98 B | $ 101.56 | 0.02 % | $ 18.8 B | ||
|
Enzo Biochem
ENZ
|
47.4 M | - | -8.98 % | $ 14.8 K | ||
|
Fulgent Genetics
FLGT
|
181 M | $ 26.78 | -0.85 % | $ 810 M | ||
|
Global Cord Blood Corporation
CO
|
451 M | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
134 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
5.91 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
983 M | - | 0.12 % | $ 80.1 M | ||
|
DermTech
DMTK
|
104 M | - | -11.32 % | $ 2.94 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
585 M | - | - | $ 10.7 B | ||
|
CareDx, Inc
CDNA
|
484 M | $ 19.47 | -1.32 % | $ 1.05 B | ||
|
Celcuity
CELC
|
113 M | $ 101.9 | -0.7 % | $ 4.02 B | ||
|
Anixa Biosciences
ANIX
|
9.98 M | $ 3.21 | -6.25 % | $ 102 K | ||
|
Heska Corporation
HSKA
|
131 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
24.1 M | - | -20.0 % | $ 1.06 M | ||
|
IQVIA Holdings
IQV
|
2.94 B | $ 226.52 | 0.26 % | $ 41.1 B | ||
|
Guardant Health
GH
|
226 M | $ 103.35 | 0.94 % | $ 12.7 B | ||
|
Aspira Women's Health
AWH
|
37.1 M | - | -6.19 % | $ 10.5 M | ||
|
Myriad Genetics
MYGN
|
709 M | $ 6.44 | -1.68 % | $ 583 M | ||
|
Illumina
ILMN
|
3.69 B | $ 135.12 | -0.15 % | $ 21.5 B | ||
|
Charles River Laboratories International
CRL
|
607 M | $ 203.88 | - | $ 10.5 B | ||
|
ENDRA Life Sciences
NDRA
|
10.8 M | $ 4.94 | -3.14 % | $ 2.65 M | ||
|
Neogen Corporation
NEOG
|
1.48 B | $ 7.12 | -0.35 % | $ 1.54 B | ||
|
National Research Corporation
NRC
|
38.5 M | $ 18.74 | 0.46 % | $ 460 M | ||
|
Quest Diagnostics Incorporated
DGX
|
1.46 B | $ 176.16 | 0.15 % | $ 19.6 B | ||
|
Biodesix
BDSX
|
106 M | $ 6.76 | -0.88 % | $ 877 M | ||
|
Motus GI Holdings
MOTS
|
18.6 M | - | -34.28 % | $ 263 K | ||
|
Laboratory Corporation of America Holdings
LH
|
1.87 B | $ 254.32 | 0.02 % | $ 21.3 B | ||
|
ICON Public Limited Company
ICLR
|
408 M | $ 182.75 | -0.51 % | $ 15.1 B | ||
|
IDEXX Laboratories
IDXX
|
1.25 B | $ 688.22 | 0.01 % | $ 56.8 B | ||
|
Pacific Biosciences of California
PACB
|
387 M | $ 1.77 | -5.85 % | $ 449 M | ||
|
Lantheus Holdings
LNTH
|
123 M | $ 66.73 | 0.07 % | $ 4.62 B | ||
|
Mettler-Toledo International
MTD
|
1.01 B | $ 1 419.64 | 0.11 % | $ 30.1 B | ||
|
Agilent Technologies
A
|
1.99 B | $ 138.31 | 0.03 % | $ 42 B | ||
|
Biomerica
BMRA
|
5.64 M | $ 2.7 | 1.9 % | $ 6.2 M | ||
|
Bioventus
BVS
|
217 M | $ 7.4 | 0.27 % | $ 464 M | ||
|
NeoGenomics
NEO
|
382 M | $ 12.33 | 0.2 % | $ 1.56 B |